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INTRODUCTION
B-cell non-Hodgkin’s lymphoma (NHL) is the seventh most com-
mon cancer in the United States with approximately 72,000 new 
diagnoses each year.1 The 1-, 5-, and 10-year survival rates for NHL 
are 79, 63, and 51%, respectively. Rituximab is a mouse/human chi-
meric monoclonal antibody targeting CD20 and induces cell killing 
through complement-dependent cytotoxicity (CDC), antibody-
dependent cell cytotoxicity, antibody-dependent cell-mediated 
phagocytosis, and direct cell apoptosis.2–6 It is effective as a single 
agent and in combination with chemotherapy in the treatment 
of CD20-postive B-cell malignancies. While efficient as first-line 
therapy, rituximab is less effective in patients with relapsed lym-
phoma.7–9 For example, only 40% of the patients with low-grade 
NHL responded again to rituximab when they had received prior 
rituximab treatment.10–12 Therefore, these patients often will require 
alternative treatments to control the lymphoma.13–15
CD46 is a membrane-linked glycoprotein that is expressed in 
humans on all cells except red blood cells. One of its functions is 
to block complement-mediated killing of autologous cells. CD46 
attaches to complement fragments C3b and C4b that are bound to 
host cells and then serves as a cofactor for their targeted destruc-
tion by the plasma serine protease Factor I. Many cancer cells upreg-
ulate CD46.16 For example, we and others have shown that CD46 
levels on blood cell malignancies were at least one order of mag-
nitude higher than on normal peripheral blood mononuclear cells 
(PBMCs).17,18 Considering that rituximab kills lymphoma cells in part 
through CDC, increased levels of CD46 may contribute to the inef-
fectiveness of rituximab in treating recurring NHL.19
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Rituximab is a mouse/human chimeric monoclonal antibody targeted toward CD20. It is efficient as first-line therapy of 
 CD20-positive B-cell malignancies. However, a large fraction of treated patients relapse with rituximab-resistant disease. So 
far, only modest progress has been made in treatment options for rituximab refractory patients. One of the mechanisms for 
rituximab resistance involves the upregulation of CD46, which is a key cell surface protein that blocks the activation of comple-
ment. We have recently developed a technology that depletes CD46 from the cell surface and thereby sensitizes tumor cells to 
 complement-dependent cytotoxicity. This technology is based on a small recombinant protein, Ad35K++ that binds with high 
affinity to CD46. In preliminary studies using a 6 × histidinyl tagged protein, we had demonstrated that intravenous Ad35K++ 
injection in combination with rituximab was safe and increased rituximab-mediated killing of CD20-positive target cells in mice 
and nonhuman primates (NHPs). The presence of the tag, while allowing for easy purification by Ni-NTA chromatography, has the 
potential to increase the immunogenicity of the recombinant protein. For clinical application, we therefore developed an Ad35K++ 
protein without His-tag. In the present study, we performed preclinical studies in two animal species (mice and NHPs) with this 
protein demonstrating its safety and efficacy. These studies estimated the Ad35K++ dose range and treatment regimen to be used 
in patients. Furthermore, we showed that intravenous Ad35K++ injection triggers the shedding of the CD46 extracellular domain 
in xenograft mouse tumor models and in macaques. Shed serum CD46 can be measured in the serum and can potentially be used 
as a pharmacodynamic marker for monitoring Ad35K++ activity in patient undergoing treatment with this agent. These studies cre-
ate the basis for an investigational new drug application for the use of Ad35K++ in combination with rituximab in the treatment of 
patients with B-cell malignancies.
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CD46 is also a receptor for a number of pathogens, including 
measles virus, Neisseria gonorrhoeae and meningitides, group A 
streptococcus, and human Herpes virus 6. We and others reported 
that CD46 is a high-affinity receptor for a series of human adeno-
virus (Ad) serotypes.20,21 Among the adenovirus serotypes that use 
CD46 is serotype 35 (Ad35). Ad35 engages CD46 via residues in 
its C-terminal trimeric fiber knob domain. We have shown that a 
recombinant fiber knob produced in Escherichia coli binds to recom-
binant CD46 cross-linking several CD46 molecules. Subsequently, a 
PCR mutation strategy was used to enhance the avidity of the tri-
mer and a series of increasingly tight binding mutant knob proteins 
were identified. The highest affinity (KD of 0.63; 23.2-fold higher than 
that of the wild-type Ad35 fiber knob) was that of a knob mutant 
with a double Asp207Gly, Thr245Ala substitution. The protein was 
named Ad35K++. For purification purposes, Ad35K++ contained 
an N-terminal 6-His tag (Ad35K++His). Binding of Ad35K++His to 
cells results in transient removal of CD46 from cells.17 In a previous 
study, we had demonstrated that Ad35K++His increased the effi-
cacy of lymphoma cell killing by rituximab both in vitro in primary 
and established human CD20-positive lymphoma/leukemia cells, 
and in vivo in tumor xenograft models.17 To extend these studies to 
nonhuman primates (NHPs), we first defined a rituximab dose that 
did not deplete CD20-positive peripheral blood cells in macaques.17 
Using this dose of rituximab, we then demonstrated that pretreat-
ment with Ad35K++His reconstituted near complete elimination of 
B cells. Ad35K++ enhancement of rituximab was more pronounced 
on CD20+CD46high cells, i.e., a subset of CD20-positive cells that 
resembles lymphoma cells.22 Further studies demonstrated that the 
treatment was well-tolerated and safe.22
All published safety and efficacy studies in mice and NHPs pre-
viously had been conducted with His-tagged Ad35K++His.17,22 
There are numerous reasons to pursue the clinical development 
of a non-His tagged protein: (i) The presence of the tag itself can 
lead to undesirable protein properties including increased immu-
nogenicity or decreased function as exemplified in a study with 
recombinant TRAIL.23 (ii) protein purification via immobilized nickel 
affinity chelate resins is more expensive than standard chroma-
tography, and (iii) due to the risk of leachable nickel the product 
might be unsuitable for patients with nickel hypersensitivities. We 
therefore developed an Ad35K++ protein that did not contain a 
 His-tag (Ad35K++). This report describes the safety, pharmacokinet-
ics, pharmacodynamics, and tissue biodistribution studies in mouse 
models and in macaques. Based on these studies, we have defined 
an Ad35K++ dose range for upcoming clinical studies. We have also 
identified shed serum CD46 as a potential biomarker for Ad35K++ 
activity.
ReSUlTS
Characterization of Ad35K++
Ad35K++ is composed of three self-trimerizing monomers con-
sisting of an affinity-enhanced fiber knob and a fiber shaft motif. 
To enhance the affinity to CD46 Asp207Gly and Thr245Ala muta-
tions were introduced into the Ad35 fiber knob.24 Only the trimer-
ized fiber knob efficiently binds to CD46. As shown in Figure  1a, 
when boiled under reducing conditions, the trimeric fiber knob 
dissociated into monomers migrating on the gel in close agree-
ment with the  predicted molecular mass of 22.7 kDa for Ad35K++. 
Without boiling, Ad35K++ appears as a trimer with a predicted 
mass around 68.0 kD. The activity of Ad35K++ was assessed using 
a CDC assay with Raji cells (Figure 1b). Raji cells are CD20-positive, 
human Burkitt’s lymphoma cells. When incubated with the human-
ized  anti-CD20 monoclonal antibody rituximab in the presence of 
normal human serum as a source for complement factors, rituximab 
kills about 50% of Raji cells by CDC under the given assay condi-
tions. CDC activity increased as expected when Raji cells were prein-
cubated for 10 hours with Ad35K++.
Figure 1  Characterization of Ad35K++. (a) Polyacrylamide sodium dodecyl sulfate (SDS) gel analysis of Ad35K++. Five micrograms of protein samples 
were loaded in Laemmli buffer containing β-mercaptoethanol with or without boiling for 5 minutes. The right graphic shows a schematic of Ad35K++ in 
the various states: Native Ad35K++ contains three monomers comprising the C-terminal, affinity-enhanced fiber knob, which interacts with CD46 and a 
shaft motif required for trimerization. During production, the monomer spontaneously trimerizes. When boiled under denaturing and reducing conditions, 
the trimer dissociates into monomers. (b) Ad35K++ activity in the rituximab complement-dependent cytotoxicity assay using Raji cells. Raji cells were 
incubated with Ad35K++ (25 µg/ml) for 8 hours followed by rituximab (15 µg/ml). After 30 minutes, normal human serum (NHS) was added and viable 
cells were counted 3 hours later based on trypan blue exclusion. Controls included incubation with phosphate-buffered saline (PBS)/NHS or rituximab/
NHS. The viability of  PBS/NHS-treated cells was taken as 100%. N = 3 independent experiments. Rituximab/NHS versus Ad35K++/rituximab/NHS: P < 0.001.
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Studies in human CD46 transgenic mice
In contrast to humans where CD46 is expressed on all nucleated 
cells, in mice, CD46 is expressed only in the testes. For PK and BD 
studies, we therefore used human CD46 (hCD46) transgenic mice 
that express CD46 in a human-like pattern.25 Mice were injected 
intravenously with Ad35K++ at a dose of 2 mg/kg. Ad35K++ 
 concentrations in serum samples were measured by enzyme-linked 
immunosorbent assay (ELISA). The ELISA detects only Ad35K++ 
capable of binding to CD46. The serum clearance curve shows a 
rapid decline during the first 24 hours with some residual Ad35K++ 
present at 72 hours (Figure  2a). Ad35K++ had a low clearance 
(CL = 0.23 l/hour/kg) and low volume of distribution (Vss = 0.07 l/kg). 
The value of AUC0-72 hour was 144,293 ng*hour/ml and the value of 
AUC0-∞ was 148,491 ng*hour/ml. AUC or “area under the curve” is 
the  time-averaged concentration of a drug circulating in blood. The 
average half-life is about 5.1 hours. For BD studies, hCD46 trans-
genic mice were injected with Ad35K++ at a dose of 2 mg/kg. Six 
hours later blood was flushed from the circulation and Ad35K++ 
concentrations in tissue lysates were measured by ELISA (Figure 2b). 
Compared to Ad35K++ concentrations per ml of serum, concen-
trations per gram tissue were at least two orders of magnitude 
lower. Relatively high levels in the lungs could be due to residual 
blood or uptake by the lung reticulo-endothelial system. Presence 
of Ad35K++ in the kidneys could indicate a potential clearance 
mechanism. 
Blood analysis. Blood samples collected at 15 minutes, 1 hour, 6 
hours, 24 hours, 48 hours, and 72 hours were analyzed for blood 
cell counts. Blood samples, collected at 72 hours, were analyzed for 
blood chemistry parameters including AST, Alk Phos, and ALT by 
the UW Medicine Clinical Laboratory. There were no abnormalities 
observed in the hematology panel and serum chemistry when com-
paring the mice treated with Ad35K++ to untreated animals (data 
not shown).
In vivo efficacy. To establish a xenograft lymphoma model, we 
intravenously injected Raji cells into immunodeficient CB17-SCID/
beige mice. In previous studies, we found that in this model, 100% 
of mice that did not receive treatment developed hind-leg paralysis 
between day 17 and 19 after Raji cell injection.17 The paralysis is 
due to tumor growth in the bone marrow, which affects the spinal 
cord. Raji tumors also form in the spleen as well as in axillary and 
mesenteric lymph nodes.17 This model therefore reflects tumor cell 
growth in patients with B-cell malignancies.
Mice received three cycles of treatment at day 8, 11, and 14 
after Raji cell injection (Figure 3a). Five groups were compared: (i) 
 phosphate-buffered saline (PBS); (ii) Ad35K++ (2 mg/kg per injec-
tion), (iii) rituximab (2 mg/kg per injection, i.v.); (iv) Ad35K++ fol-
lowed 10 hours later by rituximab (“Ad35K++→ rituximab”, this 
regimen was used in previous studies based on the kinetics of CD46 
removal from the cell surface17); and (v) Ad35K++ in combination 
with rituximab (“Ad35K++ plus rituximab”). Figure  3a shows the 
Kaplan-Meier survival data. Endpoint timing for this study was the 
day of onset of hind-leg paralysis. The study had to be stopped at 
day 37 because of skin infections in surviving mice due to multiple 
treatment rounds. Median survival for the PBS-treated group was 
18 days. Treatment with Ad35K++ increased the median survival 
by 2.5 days (from 18 to 20.5 days) (P < 0.05). The Rituximab alone 
group showed an increase in survival by 4 days (from 18 to 22 days) 
(P  <  0.05), with one animal surviving until day 32. Treatment by 
“Ad35K++→rituximab” resulted in 60% survival at day 37. Combined 
injection of Ad35K++ and rituximab resulted in survival of 20%. The 
differences between the survival curves for “Ad35K++→rituximab” 
versus “Ad35K++ plus rituximab” were not significant (P = 0.150).
CD46 shedding. Our studies on human tumor cell lines suggested 
that Ad35K++His triggers the removal of CD46 from the cell surface 
through internalization and subsequent degradation.17 Considering 
reports that CD46 at the surface of human T cells is shed by matrix 
metalloproteases upon ligation with anti-CD46 antibodies,26 we 
found that Ad35K++ also triggers matrix metalloprotease-mediated 
CD46 removal from the cell surface of human CD4+ T-cells.27 We 
speculate that both processes, CD46 internalization and shedding, 
are connected. Therefore, we measured the concentration of shed 
CD46 in serum of mice with Raji tumor following injection of 
Ad35K++ (Figure 3b). In control mice that did not receive Ad35K++, 
a slow steady increase in serum sCD46 levels was observed. 
This indicates that CD46 is shed from Raji cells at low levels. The 
mechanism for this process remains to be studied. Importantly, 
upon intravenous Ad35K++ injection, serum sCD46 levels increased 
~5-fold reaching a peak two days after Ad35K++ injection. This 
reflects an interaction of Ad35K++ with CD46 on Raji cells in vivo 
likely resulting in CD46 shedding. Serum CD46 levels can therefore 
serve a potential pharmacodynamics marker for Ad35K++ in vivo 
activity.
In summary, our PK and BD studies in hCD46tg mice demon-
strated low uptake of intravenously injected Ad35K++ by normal 
tissues with a serum half-life of 5.1 hours. Efficacy studies in the 
Raji tumor xenograft model showed that Ad35K++ significantly 
increased the therapeutic effect of rituximab. Potentially, CD46 
serum levels can be used as a pharmacodynamic marker for the 
monitoring in vivo activity of Ad35K++.
Studies in nonhuman primates
Justification for using Macaca fascicularis. Unlike most animals, in 
humans, CD46 is expressed on all nucleated cells. Of all mammals, 
only NHPs express CD46 in a pattern similar to humans.28 Our recent 
studies have shown that Ad35K++His increases rituximab-mediated 
Table 1 Ad35K++ PK parameters in M. fascicularis
Species Body weight (kg) Dose (mg/kg) CL (l/hour/kg) Vss (l/kg) t1/2 (hour) AUC0-last (ng*hour/ml) AUC0-inf (ng*hour/ml)
A14172 6.23 0.2 0.049 0.14 2.2 3,957 4,046
A14396 5.17 2 0.002 0.05 20 916,165 999,851
A14391 3.65 20 0.002 0.13 49 68,25,169 102,78,766
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CDC of primary M. fascicularis CD20+ cells.22 Rituximab  cross-
reacts with macaque CD20 and depletes B-cells after intravenous 
injection29 similar to humans. Also, this species has been used 
before in safety studies for other CD46-targeting therapeutics 
such as oncolytic measles viruses.30 M. fascicularis is therefore an 
adequate animal model to test the safety and efficacy of Ad35K++ 
in preparation for an investigational new drug submission.
NHP Ad35K++ dose range finding study. In our previous studies in 
M. fascicularis, intravenous injection of 4 mg/kg Ad35K++His (alone 
and in combination with rituximab) was well tolerated.22 To determine 
the lowest effective dose as well as the highest nonseverely toxic 
dose and correlative pharmacokinetic attributes for non His-tag 
Ad35K++, four M. fascicularis were intravenously injected with 0.05, 
0.2, 2, and 20 mg/kg of Ad35K++. Blood samples were taken daily. A 
full necropsy was performed at day 7 after Ad35K++ injection.
Toxicology. The animals were monitored by an independent group of 
veterinarians and pathologists at the Washington State Northwest 
Primate Research Center at the University of Washington. Physical 
examinations were performed daily. No changes in health, behavior, 
and weight were observed. Food intake and body temperature 
were normal.
Hematology and blood chemistry parameters did not show 
treatment-related changes. Caging and handling of animals before 
infusion of Ad35K++ caused stress-related reactions, including an 
elevation in neutrophils and decrease in lymphocytes shortly after 
infusion (4-hour time point) in all animals regardless of the Ad35K++ 
dose (Figure 4a). Cell counts returned to normal by 12 hours. One 
out of four animals (0.2 mg/kg dose) had an elevation in AST levels. 
However, ALT levels did not increase, but rather trended to decrease 
in a dose-related fashion without toxicological significance and all 
values remained within the laboratory reference range. Because of 
daily blood sampling, erythrocyte counts and hemoglobin concen-
trations decreased over time (Figure 4b). In three out of four animals 
C3 complement levels declined slightly. The RBC, Hb, and C3 values 
were however all in the normal range for this species. No changes in 
partial prothrombin time were observed at day 7 indicating normal 
coagulation.
Serum levels of the proinflammatory cytokines IFNγ, IL-6, IL-17a, 
and TNFα as well as levels indicative for Tregs (IL-10) were ana-
lyzed by a Luminex-based assay (Figure 5). TFNα was not detected 
in samples with the assay used. IFNγ levels were increased in ani-
mals that received 2 and 20 mg/kg of Ad35K++ starting 10 min-
utes after injection. For the 2 mg/kg dose, IFNγ levels returned to 
Figure 2 Pharmacokinetics (PK) and biodistribution studies in CD46tg mice. (a) Ad35K++ serum clearance. Ad35K++ serum concentrations were 
measured by enzyme-linked immunosorbent assay. Left panel: Summary of data from six animals. Right panel: Semi-log plots of average serum 
concentrations versus time profile (used for calculating the PK values). (b) Ad35K++ concentration in tissues at 6 hours after intravenous injection into 
hCD46 transgenic mice. Shown are Ad35K++ concentrations normalized to total protein as measured using the Bradford assay. N = 3.
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pretreatment levels by 8 hours, for 20 mg/kg by day 1. This indicates 
a  dose-dependent response without defined toxicologic relevance. 
IL-6 levels increased between 30 minutes and day 1 without any 
correlation to the Ad35K++ dose suggesting that IL-6 elevation 
could be related to the infusion process. In animals injected with 2 
and 20 mg/kg Ad35K++, IL-10 levels were elevated between 1 and 
4 hours postinjection, with a peak at 2 hours. The 2mg/kg dose ani-
mal showed stronger IL-10 responses than the animal that received 
20mg/kg. In the same animal, IL-17A levels declined about 50% 
during the first hour after injection. This observation needs to be 
further evaluated in additional animals. Notably, variations in base-
line levels and responses in individual animals are not uncommon 
in NHP studies.
At necropsy there were no remarkable changes in gross examina-
tion in any tissue or apparent treatment-related changes in histo-
logical analysis of sections for 30 tissues from each animal.
Pharmacokinetics. Blood samples were collected at 10 and 30 min, 
1, 2, 4, 8, 12, 24 hours and day 2, 3, 5, 7 postdosing. Ad35K++ serum 
concentrations were measured by ELISA (Figure 6). The linear plots 
for serum concentration versus time profiles that were used to 
calculate the PK parameters are shown in Figure  6 and the  semi-
log plots are presented in Supplementary Figure S1. In animals 
that received 0.05 mg/kg, Ad35K++ was only detectable during 
the first 2 hours after injection. Data for this group were therefore 
not included into the PK analyses. The total body clearance (CL) of 
Ad35K++ was 0.049 l/hour/kg at the 0.2 mg/kg dose and decreased 
to 0.002 l/hour/kg at 2 and 20 mg/kg indicating nonlinear clearance 
of Ad35K++ at lower doses (Table  1). This higher clearance of 
Ad35K++ at lower doses (0.2 mg/kg) resulted in a shorter half-life 
of Ad35K++ (2.2 hours) compared to a longer half-life of 20 and 
49 hours for the 2 and 20 mg/kg doses, respectively. The volume 
of distribution at steady-state (Vss) of Ad35K++ was also low (mean 
value  =  0.11 l/kg) suggesting that Ad35K++ distributed mainly in 
the systemic circulation.
Serum anti-Ad35K++ antibody responses
Ad35K++-specific IgG, IgM, and IgA antibodies in serum samples 
were measured by ELISA (Supplementary Figure S2). Compared to 
pretreatment levels, no detectable increase in immune responses 
was observed over the 7-day observation period for all time points 
and all doses. The animal that received the highest Ad35K++ dose 
had higher baseline anti-Ad35K++ antibody levels which could be 
the result of a previous exposure to Ad35 virus.
Pharmacodynamics
Soluble serum CD46. We measured the concentration of shed CD46 
in serum using antibodies that are specific to the extracellular 
domain of CD46 and cross-react with macaque CD46 (Figure 7). At 
the lower doses of Ad35K++, i.e., 0.05 and 0.2 mg/kg no increase in 
serum CD46 levels was evident (Figure 7a). However, at the higher 
doses of Ad35K++, a clear effect was observed. At a dose of 2 mg/
kg CD46 levels started to rise at 12 hours postinjection, peaked at 
day 3 and declined to pretreatment levels by day 7. For the 20 mg/
kg doses the decline was slower, consistent with the longer half-life 
of Ad35K++ in the animal injected with this dose. The serum CD46 
concentrations in animals used for the efficacy and biodistribution 
studies are shown in Figure 7b,c.
CD46 levels on PBMC subsets. Flow cytometry was performed on 
freshly isolated PBMCs. CD46 is expressed on all cells in nonhuman 
primates and binding of Ad35K++ should trigger a decline in CD46 
levels on these cells. In our study we focused on CD20+ B-cells 
as well as CD4+, CD8+, and PD-1+ T-cells. PD1, or Programmed 
cell Death protein 1, is a coinhibitor receptor expressed on T-cells 
that negatively regulates their activation. At a dose of 0.05 mg/kg, 
Ad35K++ had no effect on CD46 levels on these subsets (Figure 8a). 
At 0.2 mg/kg, CD46 levels decreased rapidly but returned to 
pretreatment levels at day 3 after Ad35K++ injection. Considering 
a serum half-life of ~2 hours for this dose, it is unlikely that the 
observed decline is due to CD46 masking. Both higher doses—2 
and 20 mg/kg—resulted in decreased CD46 levels on CD20+, CD4+, 
CD8+, and PD-1+ cells over the time period of analysis with a trend 
to rise again at day 7, which is consistent with our previous study 
with Ad35K++His.22 None of the Ad35K++ doses changed the 
percentage of CD20+, CD4+, CD8+, and PD-1+ cells (Figure 8b). This 
was expected because no CDC inducing antibody like rituximab 
was included in this study. This finding also supports the fact that 
Figure 3 In vivo activity of Ad35K++ in the Raji tumor xenograft mouse 
model. Immunodeficient CB17-SCID/beige mice received human 
lymphoma Raji cells via tail vein injection. (a) Three cycles of treatment 
were given at days 8, 11, and 14 after Raji cell injection (see arrows). 
Treatment groups were: (i) phosphate-buffered saline (PBS), (ii) Ad35K++ 
(2 mg/kg), (iii) rituximab (2 mg/kg), (iv) Ad35K++ followed 10 hours later 
by rituximab (“Ad35K++ → rituximab”), and (v) Ad35K++ given together 
with rituximab (“Ad35K++ plus rituximab”). Kaplan-Meier survival 
analysis with days of onset of hind leg paralysis as endpoints. N = 5. 
(b) CD46 shedding after Ad35K++ injection. Mice with established Raji 
tumors were intravenously injected with Ad35K++ at 2 mg/kg on day 
17 after Raji cell injection (see arrow). The control group received PBS. 
Serum samples before and after Ad35K++/PBS injection were collected 
and CD46 was measured by enzyme-linked immunosorbent assay using 
antibodies that recognize the extracellular domain of CD46. N = 5.
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Ad35K++ injection up to a dose of 20 mg/kg is well tolerated and 
does not negatively affect PBMCs.
Ex vivo CDC activity in CD20-positive cells from treated animals. To test 
whether Ad35K++-mediated removal of CD46 from the surface of 
CD20+ cells increases sensitivity to rituximab, we collected PBMCs 
from animals at 4 hours and day 1, 2, 3, 5, and 7 after Ad35K++ 
injection, isolated CD20+ cells by magnetic-activated cell sorting, 
and exposed them to rituximab (15 and 3 µg/ml) in the presence 
of normal M. fascicularis serum to trigger CDC. Figure 9 shows the 
relative viability of CD20+ cells compared to cells that were not 
treated with rituximab. Overall, the higher rituximab concentration 
(15 µg/ml) caused stronger CDC than the lower 3 µg/ml dose. 
CD20+ cells collected from the animal that received 0.05 mg/kg 
of Ad35K++ showed the same relative viability at all time points, 
indicating that this dose is not effective. For the 0.2 mg/kg Ad35K++ 
dose, reduced viability was observed at 4 hours and day 1 in the 
setting with 3 µg/ml rituximab which appears to be more sensitive 
to Ad35K++ effects. A clear effect of Ad35K++ on CDC sensitivity 
was however observed with CD20+ cells from animals injected with 
Figure 4 Blood analysis of macaques that received intravenous injection of Ad35K++. Ad35K++ doses were 0.05, 0.2, 2, and 20 mg/kg. (a) Changes 
in neutrophil and lymphocyte counts as well as transaminase levels that can be attributed to stress-related reactions during infusion. ALT, alanine 
transaminase (aka SGPT), AST, aspartate transaminase (aka SGOT). (b) Changes in erythrocyte counts and hemoglobin levels that can be attributed 
to blood loss due to sampling. The bottom panels show concentrations of complement factor C3 and partial thromboplastin times, an indicator for 
coagulation activity.
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2 and 20 mg/kg Ad35K++ starting at 4 hours postinjection. Similar 
to the kinetics of serum CD46 levels, an effect of Ad35K++ was seen 
until day 5. The return in cell viability percentages to pretreatment 
levels at day 7 indicates a loss of Ad35K++ effectiveness after this 
time frame.
Biodistribution. One animal was injected with Ad35K++ at a dose 
of 2 mg/kg and euthanized 6 hours later. Blood was flushed from 
the circulation and samples from 28 tissues were collected. No 
treatment-related changes were recognized during gross and 
histological examinations upon necropsy. Tissue samples were also 
collected from the 4 animals used in the dose-finding study. These 
animals were sacrificed at day 7 after Ad35K++ injection. Tissues 
samples were lysed, clarified by centrifugation and analyzed for 
Ad35K++ by ELISA. Figure 10 shows Ad35K++ in tissues normalized 
to total protein concentration. At 6 hours, the highest Ad35K++ 
levels were found in the spleen. Importantly, these levels were more 
than 200-fold lower than Ad35K++ serum levels suggesting that 
Ad35K++ stayed in the systemic circulation which coincides with 
extremely low Vss of Ad35K++. Other tissues with notable Ad35K++ 
levels included the kidneys, lymph nodes, liver, gall bladder, lung, 
and pancreas. These measurements could be due to residual 
blood in these  tissues and/or reflect potential Ad35K++ clearance 
mechanisms. A comparison of Ad35K++ levels in tissues of animals 
sacrificed at 6 hour and 7 days after injection of 2 mg/kg Ad35K++ 
indicates that most Ad35K++ is cleared by day 7. A comparison of 
Ad35K++ levels at day 7 in animals injected with 0.05, 0.2, 2, and 
20 mg/kg revealed dose dependence of Ad35K++ presence in 
tissues (Figure  10a; Supplementary Figure S3). As expected, the 
highest tissue levels were found in animals injected with 20 mg/
kg. Specifically, residual levels (comparable to those found at 6 
hours after injection of 2 mg/kg) were found in the liver, pancreas, 
and thyroids (Figure  10b). Overall, the Ad35K++ levels found in 
tissues were considered trivial compared to the Ad35K++ levels in 
the circulation. PBMCs from this animal were also used to measure 
CD46 levels on PBMC subfractions and sensitivity to rituximab CDC 
in vitro (Supplementary Figure S4) and the data support our findings 
described for Figures 8 and 9.
Efficacy study with Ad35K++. Rituximab cross-reacts with macaque 
CD20 and depletes B-cells after intravenous injection similar to what 
is observed in humans. Previously, we established that rituximab at 
a dose of 0.01 mg/kg had no effect on CD20+ cell levels.22 We then 
showed that  injection of Ad35K++His two or three days before 
injection of 0.01 mg/kg of rituximab resulted in a sharp decrease in 
the percentage of CD20+ cells suggesting that Ad35K++-mediated 
downregulation of CD46-sensitized CD20 cells to rituximab CDC 
when given at dose of 0.01 mg/kg. CD20 depletion lasted for ~5 days. 
To assess the potency of our new Ad35K++ preparation, we used 
the same treatment regimen as in the previous study. One animal 
received Ad35K++ at a dose of 4 mg/kg followed 2 days later by 
rituximab (0.01 mg/kg) (Figure 11). CD46, CD20, and CD4 on PBMCs 
were monitored for 14 days. In agreement with our dose-finding 
study (see Figure 8), after Ad35K++ injection, CD46 levels declined 
on CD20+ cells as well as other PBMC subsets, e.g., CD4 cells and 
returned to pretreatment levels by day 14. Injection of rituximab 
resulted in a >30% decline in the percentage of peripheral blood 
CD20 cells. CD20 levels returned to preinjection levels by day 14. 
Figure 5 Serum cytokine concentrations in M. fascicularis. Interferon-γ (IFNγ), interleukin 6 (IL-6), and IL-17a are proinflammatory cytokines. IL-10 is an 
anti-inflammatory cytokine considered to be a marker for regulatory T cells.
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In contrast, rituximab had no effect on the level of cells that do not 
express the CD20 target, e.g., CD4 cells. These data are in agreement 
with our previous study performed with Ad35K++His and indicate 
that the two Ad35K++ preparations have comparable potencies 
with regards to enhancing rituximab CDC in vivo.
Summary of NHP studies. In summary, the dose range finding 
study in M. fascicularis did not show dose-limiting toxicities, which 
potentially warrants the analysis of higher doses of Ad35K++ to 
assess dose-limiting toxicity in this species. Therapeutic effects in 
NHP of Ad35K++ doses lower than 0.2 mg/ml are not expected. The 
therapeutic effect on PBMCs at 2 and 20 mg/kg did not differ greatly. 
However, this does not necessarily apply to lymphoma cells in vivo 
where CD46 levels are higher than on PBMCs. The PK and PD data 
indicate that the period of Ad35K++ activity in vivo is 5 days with a 
half-life in blood of at least 20 hours. The study also corroborated 
the value of serum CD46 levels as a PD marker.
DISCUSSION
To date, only modest progress has been made in treatment options 
for patients with rituximab-refractory B-NHL with the most effec-
tive agents demonstrating progression-free survival of less than 
1 year. Furthermore, outcomes for patients with more aggres-
sive histologies and rituximab-resistance are even more dismal.7–9 
We developed Ad35K++ as a cotherapeutic to enhance rituximab 
therapy and, potentially, overcome treatment resistance. Ad35K++ 
transiently removes CD46 from cells and thereby sensitizes them 
to CDC triggered by rituximab. CD46 shedding and CD46 flow 
cytometry data indicate that the period of decreased surface CD46 
expression lasts about 3 days in the Raji xenogaft models and about 
5 days in NHPs. Several mechanisms for CD46 removal by Ad35K++ 
can be considered: Our previous in vitro data using tumor cells 
indicate internalization of CD46 and subsequent degradation.17 
Internalization of CD46 through macropinocytosis in lymphoid and 
nonlymphoid cells was also reported upon CD46 crosslinking by 
multivalent antibodies or by measles virus.31 In this study,  incubation 
with monoclonal antibodies against CD46 did not trigger long-term 
CD46 downregulation. The latter is consistent with our observa-
tion that anti-CD46 mAbs did not significantly enhance rituximab 
CDC in vitro.17 Another potential pathway of Ad35K++ mediated 
CD46 removal from the cell surface is cleavage and shedding of the 
extracellular domain. In epithelial cells32 and T cells,26 upon CD46-
crosslinking, the CD46 ectodomain is shed after cleavage by matrix 
metalloproteinases, and its two intracytoplasmic tails are cleaved by 
the presenilin-gamma secretase enzymatic complex. Previous stud-
ies in primary human T cells also showed that Ad35K++ triggered 
CD46 shedding.27 It was therefore not surprising that we observed 
shed CD46 in the serum of macaques upon Ad35K++ injection. Our 
report here in the Raji xenograft model demonstrated Ad35K++-
mediated shedding from tumor cells in vivo. This study also dem-
onstrated that low levels of CD46 shedding even without Ad35K++ 
appears to be an ongoing process from the tumor cells. In this con-
text, it is notable that shed CD46 was documented in the sera of 
Figure 6 Ad35K++ serum concentrations versus time profiles following intravenous administration of Ad35K++ at 0.05, 0.2, 2, or 20 mg/kg in M. 
fascicularis. Serum dilutions ranging from 1:10 to 1:100,000 were used to achieve the optical density (OD) readings that were in the range of the standard 
curve. The dilution factor is shown in the lower right corner of each panel.
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cancer patients.33 These findings on in vivo CD46 shedding have 
implications for our upcoming clinical trial in patients with B  cell 
malignancies and indicate that serum CD46 can serve as a valuable 
marker for the in vivo function of Ad35K++.
Efficacy studies in a Raji tumor xenograft model are relevant for 
the clinical translation of our approach. While rituximab treatment 
in this aggressive xenograft lymphoma model had only a marginal 
effect on survival, this was increased significantly with the addition 
of Ad35K++ more than doubling survival times in comparison to 
rituximab alone. Our previous studies—which used the research 
grade Ad35K++(His) in combination with rituximab—were per-
formed with an interval of 6 to 12 hours between Ad35K++(His) 
dosing and rituximab dosing. Most rituximab refractory patients 
that would be candidates to be treated with Ad35K++ in upcom-
ing trials will have residual rituximab in the blood due to the long 
 half-life of the antibody. Considering this, the kinetics of CD46 
downregulation in vitro,17,22 and the convenience of concomitant 
administration in the clinic, in this report we tested simultane-
ous injection of Ad35K++ and rituximab. Differences between 
the simultaneous and sequential treatment groups were not 
statistically significant although there appeared to be a trend of 
the sequential groups to be slightly superior in terms of survival. 
It has to be considered that the 5.1 hour half-life of Ad35K++ in 
hCD46tg mice is much shorter than the 20 hour one we found for 
macaques and most likely humans, which limits the predictive 
value of the murine dosing schedule studies.
Ad35K++ injection alone in mice had a small but significant ther-
apeutic effect. This is in agreement with our previous in vitro CDC 
studies in which Ad35K++His triggered cell death in the absence 
of rituximab and complement.17 The function of CD46 is not only 
restricted to blocking the complement cascade. A series of stud-
ies show that CD46 ligation modulates the phenotype of T- and 
B-cells.34,35 Binding of pathogenic bacteria to CD46 on epithelial cells 
is associated with apoptotic cell death.36 Signaling upon Ad35K++ 
binding to lymphoma cells has not been studied yet. However, our 
data suggest that it might affect tumor cell viability to some degree.
The safety of Ad35K++ infusion was assessed in the 
 hCD46-transgenic mouse model with 2 mg/kg of Ad35K++ and 
in M. fascicularis with a maximum dose of 20 mg/kg. In both spe-
cies, no remarkable Ad35K++ treatment-related changes in 
Figure 7 Soluble CD46 serum levels in M. fascicularis. CD46 was measured by enzyme-linked immunosorbent assay with human CD46 extracellular domain 
(ECD)-specific antibodies that cross-react with macaque CD46. (a) Results from animals that were in the dose finding study which went for 7 days. (b,c) 
Results from animals that were in the 14-day efficacy study (b) and 6-hour biodistribution study (c). Ad35K++ doses are indicated in each graph.
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hematological parameters were found. Tissue histology upon nec-
ropsy was normal. In hCD46tg mice and macaques, we found only 
minimal amounts of Ad35K++ taken up by normal tissues. CD46 
levels on normal tissues are low and CD46 in epithelial tissues is 
not readily accessible to intravenously injected ligands.17,18,37,38 In 
contrast, CD46 is overexpressed on circulating malignant cells.18 We 
therefore speculate that this confers some preference of Ad35K++ 
interaction with lymphoma cells. In this context, we have previously 
shown that Ad35K++ strongly increased rituximab efficacy in a 
double transgenic (human CD46/human CD20) mouse model with 
syngeneic hCD20-positive tumors that expressed hCD46 at levels 
seen in human lymphoma cells.17
The efficacy of Ad35K++ in NHPs was evaluated based on 
four parameters: (i) concentrations of shed CD46 in the serum, 
(ii)  removal of CD46 from the surface of PBMC subsets by flow 
cytometry, (iii) enhancement of rituximab-triggered cell killing in 
vitro, and (iv) enhancement of rituximab-triggered CDC of CD20+ 
cells in vivo. These studies suggest that a dose of 2 mg/kg may be 
effective in humans while doses below 0.2 mg/kg have no effect. 
Analysis of Ad35K++ pharmacodynamics indicated an interval of 
demonstrable effectiveness of approximately 5 days and would 
be well suited to pairing with the standard weekly rituximab cycle. 
Based on this, weekly treatment with Ad35K++/rituximab will be 
incorporated into the clinical trial design. In our first-in-human 
Figure 8 Flow cytometry on M. fascicularis PBMC. (a) CD46 levels were assessed based on the mean fluorescence intensity (MFI) after staining with a 
goat polyclonal anti-CD46 antibody followed by an anti-goat Alexa Fluor 488 antibody. The relative percentage of CD46 MFI compared to pretreatment 
controls is shown. (b) Percentage relative to pretreated controls of CD20-, CD4-, CD8-, and PD-1-positive PBMC subsets. Differences in the baseline levels 
of subsets between individual animals are common in NHPs.
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clinical trial, we plan to combine Ad35K++ with rituximab given at 
the standard therapeutic dose (375 mg/m2). Lower rituximab doses 
and alternate schedules could be considered for later stage trials. As 
our studies in NHPs demonstrated, Ad35K++ can convert a subther-
apeutic dose of rituximab (0.01 mg/kg or about 0.12 mg/m2) into a 
B-cell depleting dose. Notably, monkey B-cells appear to be more 
sensitive to rituximab than human B-cells.39
Ad35K++ is a protein derived from an adenovirus with low sero-prev-
alence of pre-existing anti-Ad35 antibodies in humans.17 However, our 
previous study in NHPs showed that antibodies were generated after 
Ad35K++ infusion.22 The effect of multiple cycles of Ad35K++/ritux-
imab infusion on the development of anti-Ad35K++ antibodies and 
their influence on safety and Ad35K++ efficacy remains to be assessed 
in future studies. Ad35K++ immunogenicity is unlikely to be a signifi-
cant issue in NHL patients who have a suppressed immune system, 
both related to their disease and due to rituximab treatment which 
leads to depletion of B-cells.6,40–42 In fact, rituximab is used clinically to 
suppress antibody production in order to prevent humoral-mediated 
transplant rejection.40 Further, with the non-His-tag-engineered ver-
sion of Ad35K++, the risk of generating an immune response may 
be further reduced. Our studies in NHPs have, so far, not assessed the 
effect of multiple cycles of Ad35K++/rituximab injection on the devel-
opment of anti-Ad35K++ antibodies and their influence on safety and 
efficacy. The design of our clinical trial involves four treatment cycles 
with an interval of 1 week and a potential maintenance phase with 
treatment every 2 months for up to 2 years. Before investigational new 
drug submission, we will perform an additional NHP study with four 
cycles of Ad35K++/rituximab treatment and evaluate anti-Ad35K++ 
antibody levels and safety after each treatment cycle. In parallel, to 
assess Ad35K++ efficacy, sCD46 serum levels and CD46 levels on 
PBMCs will be measured before and 3 days after each treatment cycle. 
If there is evidence of anti-Ad35K++ antibody associated toxicity or 
reduced effectiveness after multiple cycles, we will pursue approaches 
to suppress antibody development. This will include approaches that 
have been tested clinically (e.g., pentostatin, cyclophosphamide, pred-
nisolone,43,44 or others that are currently under development.45,46
Overall, the preclinical studies reported here have created the basis 
for selection of key trial parameters for human clinical testing and 
provide new insights in the mechanism of action of our cotherapeu-
tic Ad35K++.
MATeRIAlS AND MeTHODS
Ad35K++
Ad35K++ was produced by EirGenix (Taipei, Taiwan) (Lot H15003) in a 2-l 
fermentor based on a non-His tagged construct in E. coli. Purification of 
Ad35K++ involved three chromatography steps. Endotoxin levels were 
Figure 9 Rituximab complement-dependent cytotoxicity (CDC) assay with CD20+ cells from Ad35K++-injected M. fascicularis. PBMCs were collected 
at the indicated time points and CD20+ cells were isolated. CD20+ cells were subjected to treatment with rituximab (15 and 3 µg/ml) and fresh serum 
from an animal that did not receive Ad35K++ (as a source of complement) and viable cells were counted. The viability of untreated cells (no rituximab/
complement) was taken as 100%. “Pre”: Relative viability of CD20+ cells taken from animals before Ad35K++ injection. These levels reflect the sensitivity 
of CD20+ cells to rituximab CDC. The bars show the relative viability of CD20+ cells compared to untreated cells (no rituximab/complement).
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1.7 EU/mg. The protein was stored at −80 °C in 25 mmol/l Tris pH 7.0/15% 
glycerol.
Cell lines
Human lymphoma Raji cells (ATCC CCL-86) were cultured in RPMI 1640 
medium supplemented with 10% fetal bovine serum and with L-glutamine 
and Pen/Strep in a humidified CO2 incubator at 37 °C as previously described.
8
Antibodies
Rituximab (NDC 50242-051-21) was obtained from Genentech (South San 
Francisco, CA). Anti-Ad35K++His was generated in rabbits immunized with 
Ad35K++His using services of Custom-Hybridoma.com (A division of PickCell 
Laboratories, Amsterdam, the Netherlands). The mouse anti-human CD46 
monoclonal antibody (clone 344519) and the goat anti-human CD46 poly-
clonal antibody were from R&D Systems (Minneapolis, MN). Another mouse 
anti-human CD46 monoclonal antibody (clone J4-48) was from Chemicon 
(Raleigh, NC). The goat anti-mouse IgG-horseradish peroxidase (HRP), PE 
mouse anti-human CD20 (clone 2H7), PE mouse anti-human CD4 (clone 
M-T477), PE mouse anti-human CD8 (clone RPA-T8), PE mouse  anti-human 
CD14 (clone M5E2), and PE-Cy7 mouse anti-human CD25 (clone M-A251) 
were from BD Biosciences (San Jose, CA). PE mouse anti-human CD279 (PD-
1) (clone EH12.2E7) was from BioLegend (San Diego, CA). Alexa Fluor 488 
donkey anti-goat was from Life Technologies (Carlsbad, CA). FcR blocking 
reagents human was from Miltenyi Biotec (San Diego, CA).  Goat-anti-monkey 
IgG+IgA+IgM-HRP was from MyBioSource (San Diego, CA).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
Samples were either boiled at 95 °C for 5 minutes in a water bath to evalu-
ate Ad35K++ monomer or not boiled to evaluate the Ad35K++ homotrimer 
which unlike many other proteins does not dissociate in sodium dodecyl sul-
fate without heat treatment. Laemmli sample buffer and β-mercaptoethanol 
Figure 10 Ad35K++ concentrations in tissues 6 hours after injection into M. fascicularis. A total of 100 mg of tissue in phosphate-buffered saline 
(PBS)/0.1% Tween 20 were lysed by freeze/thawing and sonication. Lysates were cleared by centrifugation and subjected to an Ad35K++ ELISA. 
Corresponding lysates of each tissue from an untreated animal were spiked with Ad35K++ protein for standard curves. Ad35K++ concentrations 
were normalized to total protein concentrations in each sample. (a) Comparison of Ad35K++ tissue concentrations at 6 hours (animal A14401, see 
Supplementary Table S1) and at day 7 (animal A14369) after injection of 2 mg/kg of Ad35K++. (b) Comparison of Ad35K++ tissue concentrations at 6 
hours after injection of 2 mg/kg Ad35K++ (animal A14401) and at day 7 after injection of 20 mg/kg Ad35K++ (animal A14361).
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were added to all samples. A total of 5 μg of protein sample were loaded per 
lane of 4–15% Mini-PROTEAN TGX gels. Gels were stained with Coomassie 
Blue.
Complement-dependent cell killing assay (CDC)
Raji cells were incubated with PBS or 25 μg/ml Ad35K++. Eight hours later, 
15 µg/ml of rituximab was added to cells and incubated at room tempera-
ture for 30 minutes. Normal human serum was then added to a final dilution 
of 1:5 and cells were incubated at 37 °C for another 3 hours. Viable cells in 
each well were counted after trypan blue staining. Each sample was tested 
in triplicate and each well was counted four times.
sCD46 ELISA
The ELISA was performed using the goat polyclonal anti-CD46 antibody 
and the mouse monoclonal antibody J4-48 directed against human CD46. 
Recombinant CD46 extracellular domain protein (sCD46, Sino Biological, 
Beijing, China) was used for the standard curve. The detection limit of the 
sCD46 ELISA was 0.5 ng/ml. The antibodies cross-react with macaque CD46.
Ad35K++ ELISA
The ELISA consisted of a polyclonal rabbit antibody directed against the 
Ad35 fiber knob as capture antibody. Binding of Ad35K++ was detected 
with sCD46 followed by anti-CD46 mAb and goat anti-mouse IgG-HRP. 
Mouse serum dilutions of 1:500 with blocking buffer resulted in optical den-
sity values that were in the linear range of the standard curve. For the stan-
dard curve, a 1:500 dilution of normal hCD46tg mouse serum was spiked 
with purified Ad35K++, respectively. For the measurement of Ad35K++ in 
monkey serum, the dilutions indicated in the figure legends were used. 
Corresponding dilution of serum from a nontreated macaque were spiked 
with purified Ad35K++. The detection limit of the ELISA is 0.015 μg/ml.
Animal studies—mice
All experiments involving animals were conducted in accordance with the 
institutional guidelines set forth by the University of Washington. Mice were 
housed in specific-pathogen-free facilities.
hCD46-transgenic mice
C57Bl/6-based transgenic mice that contained the human CD46 genomic 
locus and provide CD46 expression at a level and in a pattern similar to 
humans were described earlier.25 These mice are also interferon receptor 
knock-out. Ad35K++ was injected retroorbitally. Blood samples were taken 
by submandibular bleeding.
Preparation of tissues for Ad35K++ ELISA
Six hours after Ad35K++ injection, animals were sedated and blood was 
flushed from the circulation with 5 ml of PBS using the heart as a pump. 
Hundred milligrams of tissues in PBS-0.05%Tween20 were homogenized 
using the TissueRuptor system (Qiagen, Valencia, CA), sonicated for 20 sec-
onds, and subjected to three freeze/thaw cycles. Cell debris was spun down 
and supernatants from lysed tissues were used in the Ad35K++ ELISA at 1:10 
dilutions. For standard curves, 1:10 dilutions of lysates from corresponding 
tissues from a nontreated mouse were spiked with purified Ad35K++.
Animal studies—NHPs
All NHP studies were performed by the Washington National Primate 
Research Center at the University of Washington under IACUC protocol 
 3108-03. Ages and weights of all animals are shown in Supplementary Table 
S1. All blood cell counts and chemistry analyses were done by UW Laboratory 
Medicine. The day before infusion the required amount of Ad35K++ was 
Figure 11 Effect of Ad35K++ on rituximab killing of CD20 cells in M. fascicularis. Ad35K++ (4 mg/kg) was injected 10 minutes after preinjection samples 
(pre) were collected. Rituximab (0.01 mg/kg) was injected 10 minutes after day 2 blood samples were collected. The upper graph shows CD46 levels 
on CD20 cells (red lines) and the percentage of CD20+ cells compared to baseline (blue line). The lower graphs show a similar analysis of CD4+ cells.
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dialyzed against 2 l of PBS overnight at 4 °C. The material was then filtered 
through a 0.2-µm filter and injected into the arm vein of sedated animals 
over a time period of 8 minutes.
Pharmacokinetics analysis
PK analysis of Ad35K++ serum concentration versus time data was per-
formed using Phoenix for WinNonlin Program, version 6.3 (Phoenix 
WinNonlin Copyright © 2012, Pharsight Corporation, Mountain View, CA). 
PK parameters were estimated using a noncompartmental model method. 
Area under the curve (AUC) was calculated using the linear trapezoidal rule. 
Last three concentration time points were used to determine the half-life.
PBMC flow cytometry
Blood samples were drawn into ethylene-diamine-tetra-acetic acid tubes. 
Per 0.3 ml of whole blood, 3 ml of 1× Pharm Lyse Buffer (BD Biosciences, 
San Jose, CA) were added and incubated at room temperature for 15 min-
utes. Cells were spun down, supernatant was removed, and the pellet was 
washed with PBS supplemented with 1% heat-inactivated FBS (fluores-
cence-activated cell sorting buffer). After a second spin, cells were resus-
pended in 100 μl fluorescence-activated cell sorting buffer supplemented 
with 1 μl human Fc blocking reagent and incubated on ice for 10 minutes. 
Hundred microliters of antibody staining solution were added with the fol-
lowing antibodies and allowed to incubate on ice for 30 minutes: PE mouse 
anti-human CD20 (clone 2H7), PE mouse anti-human CD4 (clone M-T477), PE 
mouse anti-human CD8 (clone RPA-T8), PE mouse anti-human CD14 (clone 
M5E2), PE-Cy7 mouse anti-human CD25 (clone M-A251), PE anti-human 
CD279 (clone EH12.2E7), and goat polyclonal anti-human CD46. In addition, 
corresponding  isotype-matched controls were used: PE mouse IgG1, PE 
mouse IgG2a, PE mouse IgG2a, and PE-Cy7 mouse IgG1. Cells were washed 
once and resuspended in 100 µl fluorescence-activated cell sorting buffer 
supplemented with 1 μl of Alexa Fluor 488 donkey anti-goat and incubated 
on ice for 30 minutes. Samples were washed once more and analyzed on a 
BS LSRII flow cytometer (BD Biosciences). PBMCs were gated for size first, 
then, doublets were excluded. Single cells were gated for the respective cell 
surface markers.
Magnetic-activated cell sorting for CD20+ cells
PBMCs of 1 ml of whole blood were isolated via RBC lysis and CD20+ cells 
were purified using nonhuman primate CD20 microbeads (Miltenyi Biotec) 
according to the manufacturer’s instructions.
Ex vivo analysis of complement-dependent cell killing using PBMCs 
from Ad35K++-treated animals
Purified CD20+ cells from the sorting described above were divided into 
wells of a 96-well plate and taken up in 100 μl of RPMI 1640 medium sup-
plemented with 10% heat-inactivated FCS and 1× penicillin/streptomycin. 
Rituximab was added at 15 and 3 μg/ml, respectively and incubated at 37 °C 
for 30 minutes. Next, 7.5 μl normal nonhuman primate serum were added 
and cells were incubated at 37 °C for 3 hours. Cells were transferred back to 
microcentrifuge tubes, spun down, and the supernatant removed leaving 10 
μl medium on the cells. Samples were mixed with 10 μl Trypan blue staining 
solution and enumerated using a hemocytometer.
Cytokine detection
Serum samples were analyzed using the Milliplex nonhuman primate cyto-
kine premixed immunoassay kit from Millipore (Billerica, MA).
Anti-Ad35K++ antibody ELISA
Polyclonal Ad35 fiber antibody was absorbed on ELISA plates followed by 
Ad35K++ protein at a saturating concentration. Dilutions of monkey serum 
(1:10, 1:100, 1,000) were added and binding was detected with goat-anti 
monkey IgG+IgA+IgM-HRP.
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